Dana-Farber researchers present major cancer clinical trial results, including AI-driven data analysis, at ESMO Congress 2025.
Key Details
- 1Dana-Farber leads four phase 3 studies in breast, lung, and bladder cancer at ESMO Congress 2025.
- 2Key trials address advanced breast cancer treatment, NSCLC first-line therapy, and ctDNA-guided therapy in bladder cancer.
- 3Patient-reported data from SERENA-6 trial shows improved quality of life for metastatic breast cancer patients.
- 4Presentation of AI-generated synthetic cohorts from a 19,164 patient metastatic breast cancer dataset for real-world data analysis.
- 5Blood biomarker (KIM-1) study may help guide advanced kidney cancer treatment decisions.
- 6ESMO 2025 held in Berlin, Oct 17–21, with global participation.
Why It Matters
The use of AI to generate synthetic cohorts and analyze real-world oncology data can accelerate clinical trials and protect patient privacy, representing significant advancements for radiology, cancer informatics, and AI communities. These developments offer pathways to improved research collaboration and personalized cancer care.
Source
EurekAlert
Related News
•EurekAlert
AI-Powered OCT Enables Rapid 'Optical Biopsy' for Early Endometrial Cancer Detection
A team at Washington University has developed a catheter-based 3D OCT system with AI to quickly and noninvasively detect early endometrial cancers.
•EurekAlert
AI Clinical Reasoning in Diagnostics and Digital Fatigue in Healthcare
Recent JMIR features explore large language models in clinical diagnostics and digital fatigue among healthcare professionals.
•EurekAlert
AI Method Protects Sensitive Data in ECGs While Retaining Clinical Value
Researchers developed an AI model (PP-VAE) that safeguards sensitive personal data in electrocardiograms without sacrificing clinical utility.